We investigated the pharmacology of three novel compounds, Org 27569, Org 27759 and Org 
Introduction
defined as the orthosteric binding site (Neubig et al., 2003) . It is now recognised, however, that GPCRs may also contain allosteric binding sites for endogenous and/or synthetic ligands (Christopoulos and Kenakin, 2002) . Allosteric sites are topographically distinct from the orthosteric site, hence the structural features that determine ligand binding to allosteric sites are different from those of orthosteric ligands. In contrast to the direct effects on receptor function that are mediated by orthosteric ligands, allosteric drugs act by modulating receptor activity through conformational changes in the receptor that are transmitted from the allosteric to the orthosteric site and/or to effector coupling sites (Christopoulos, 2002) .
The simplest allosteric interaction can be described by the allosteric ternary complex model (TCM; Figure 1 ), where the effect of an allosteric ligand is to change the affinity of an orthosteric ligand for the receptor, and vice versa (Ehlert, 1988; Lazareno and Birdsall, 1995) . Mechanistically, allosteric modulation of affinity reflects a conformational change in the receptor that may lead to an alteration in the dissociation kinetics of a preformed orthosteric ligand-receptor complex; this effect on dissociation kinetics cannot occur if interacting ligands recognize the same binding site, and is thus diagnostic of an allosteric effect (Kostenis and Mohr, 1996; Christopoulos, 2000) . More recently, data have been presented to suggest that allosteric modulators may affect the efficacy of orthosteric ligands in addition to, or independently of, effects on orthosteric ligand binding, necessitating the development of more complex models of allosteric modulation (see Christopoulos and Kenakin, 2002 , and references therein).
To date, the main principle underlying GPCR-based drug discovery has invariably been the optimisation of lead molecules towards the orthosteric site on the GPCR to obtain selectivity of action. However, allosteric modulators offer advantages This article has not been copyedited and formatted. The final version may differ from this version. not readily available with orthosteric ligands. For example, allosteric drugs that affect affinity (but not efficacy) would be advantageous in that they would boost or dampen the effect of the endogenous ligand without disrupting the inherent spatial and temporal patterns of physiological signalling (May and Christopoulos, 2003) . CB 1 receptor pharmacology is the subject of intense academic and commercial research effort directed at the treatment of obesity (Horvath, 2003) , pain (Iversen and Chapman, 2002; Pertwee 2001) , inflammation (Rice et al, 2001) , osteoporosis (Idris et al, 2005) , cancer (Bifulco & DiMarzo, 2002) , multiple sclerosis (Pertwee, 2002) and cardiovascular disorders (Randall et al, 2002) . There is ample evidence that the levels of endocannabinoids are altered in these pathophysiological situations.
Allosteric enhancers of the cannabinoid CB 1 receptor would thus offer the prospect of producing clinically useful compounds that do not display the CNS side-effects that are characteristic of direct receptor agonism. In this investigation we provide the first evidence for an allosteric binding site on the cannabinoid CB 1 receptor, as revealed by the pharmacology and mode of action of a novel class of synthetic small molecules ( Figure 2 ). 5-Chloro-3-ethyl-1H-indole-2-carboxylic acid (1-benzyl-pyrrolidin-3-yl)-amide, 2-enedioic acid salt).
Material and Methods

Materials
Radioligand Binding Assays
Mouse Brain Membrane Preparation
Whole brains from adult male MF1 mice were suspended in centrifugation buffer (320 mM sucrose, 2 mM EDTA, 5 mM MgCl 2 ) and the tissues were homogenized with an Ultra-Turrex homogenizer. Tissue homogenates were centrifuged at 1600 g for 10 minutes and the resulting supernatant collected. This pellet was resuspended in centrifugation buffer centrifuged as before and the supernatant collected. Supernatants were combined before undergoing further centrifugation at 28,000 g for 20 minutes. The supernatant was discarded and the pellet resuspended in buffer A (50 mM Tris, 2 mM EDTA, 5 mM MgCl 2 at pH 7.0) and incubated at 37°C for 10 minutes. Following the incubation, the suspension was centrifuged for 20 minutes at 23,000 g. After resuspending the pellet in buffer A, the suspension was incubated for 40 minutes at room temperature before a final centrifugation for 15 minutes at 11,000 g. The final pellet was resuspended in buffer B (50 mM Tris, 1 mM EDTA, 3 mM MgCl 2 ) and the final protein concentration, determined by Bio-Rad Dc kit, was 1 mg ml -1 . All centrifugation procedures were This article has not been copyedited and formatted. The final version may differ from this version. Harvester) and Whatman GF/B glass-fibre filters that had been soaked in wash buffer at 4°C for 24 h. Each reaction tube was washed five times with a 4-ml aliquot of buffer. The filters were oven-dried for 60 min and then placed in 5 ml of scintillation fluid (Ultima Gold XR, Packard), and radioactivity quantitated by liquid scintillation spectrometry. Specific binding was defined as the difference between the binding that occurred in the presence and absence of 1 µM of the corresponding unlabelled ligand and was 70 -80% of the total binding.
Dissociation Kinetics
Dissociation kinetic assays were performed with the CB 1 receptor agonist, [ 3 H]CP55940 (0.7 nM), 1 mg ml -1 bovine serum albumin (BSA) and 50 mM Tris buffer containing 0.1mM EDTA and 0.5mM MgCl 2 (pH 7.4), total assay volume 500 µl. We utilised the 'isotopic dilution' method to measure the dissociation rate constant for [ 3 H]CP55940 from brain membranes (see Christopoulos, 2000) .
This article has not been copyedited and formatted. The final version may differ from this version. were used. To determine the non-specific binding, experiments were also performed in the presence of 1µM of the unlabelled ligand. Binding was terminated by addition of ice-cold wash buffer (50 mM Tris buffer, 1 mg ml -1 BSA) and vacuum filtration using a 24-well sampling manifold (Brandel Cell Harvester) and Whatman GF/B glass-fibre filters that had been soaked in wash buffer at 4 °C for 24 h. Each reaction tube was washed five times with a 4-ml aliquot of buffer. The filters were oven-dried for 60 min and then placed in 5 ml of scintillation fluid (Ultima Gold XR, Packard), and radioactivity quantitated by liquid scintillation spectrometry. Specific binding was defined as the difference between the binding that occurred in the presence and absence of 1 µM unlabelled ligand and was 70 -85% of the total binding.
Mouse Isolated Vas Deferens Assay
Vasa deferentia were obtained from albino MF1 mice weighing 26 to 40 g. Each tissue was mounted in a 4 ml organ bath at an initial tension of 0.5g. This article has not been copyedited and formatted. The final version may differ from this version. 
Data Analysis
Radioligand competition binding isotherms for the interaction between orthosteric ligands were analyzed using Prism 4.01 (GraphPad Software, San Diego, CA) according to the following logistic function:
( 1) where Y denotes the percent specific binding, Top and Bottom denote the maximal and minimal asymptotes, respectively, [I] denotes the inhibitor concentration and IC 50 denotes the inhibitor potency (midpoint location) parameter.
The interaction between each radioligand and the test modulators was analyzed according to the following allosteric ternary complex model of interaction: This article has not been copyedited and formatted. The final version may differ from this version. For the dissociation kinetic experiments, the decay in radioligand binding over time was analyzed according to the following two-phase exponential decay model:
where Span1 and Span2 denote the percentage of each phase, Plateau denotes the minimal asymptotic value, and k 1 and k 2 denote the rate constants for the components defined by Span1 and Span2, respectively. An extra-sum-of-squares (F-test) was used to determine whether the data were significantly better fitted to this model as compared to a simpler model characterized by a single Span and k value.
Concentration-response data were fitted empirically to the following four-parameter logistic equation:
where Y denotes effect, [A] the concentration of agonist, n H the Hill slope, pEC 50 the negative logarithm of the midpoint location parameter, and E max and Basal the upper and lower asymptotes, respectively. An extra-sum-of-squares (F-test) was used to determine whether the data were significantly better fitted assuming separate values for the Basal and n H parameters across each dataset in the absence relative to presence of test compound, compared to common values for each parameter.
This article has not been copyedited and formatted. The final version may differ from this version. In practice, all affinity (K B ), potency (EC 50 ) and cooperativity (α) parameters were estimated as logarithms (Christopoulos, 1998) .
Operational Model-Fitting
The functional interaction between test compounds and the orthosteric agonist, WIN 55,212-2, in the mouse isolated vas deferens was fitted to the following operational model of allosterism (see Appendix for derivation):
where E denotes the effect, β denotes an empirical proportionality constant that quantifies the change in stimulus imparted to the receptor by the agonist in the presence of modulator, E m denotes the maximum possible effect, τ is an operational measure of orthosteric ligand efficacy, and n is a logistic slope factor that governs the shape of the stimulus-response function.
[A], K A and α are as defined above. 
Statistics
Results
Equilibrium Binding Assays
In equilibrium binding experiments with the orthosteric agonist probe, 
Mouse Vas Deferens
The effects of the modulators on CB 1 receptor function were initially investigated using the mouse vas deferens as an in vitro model of CB 1 receptor activity. As shown in Figure 5A -C, the compounds by themselves neither inhibited
This article has not been copyedited and formatted. The final version may differ from this version. nor enhanced electrically-evoked contractions at the concentrations that were used (up to 1 µM), suggesting that they are neither allosteric agonists nor inverse agonists. This is in contrast to the effect of the established CB 1 receptor inverse agonist SR141716A, which significantly increases electrically-evoked contractions under the same assay conditions ( Figure 5D ). The functional effects of the compounds on the inverse agonism displayed by SR141716A in the mouse vas deferens is the subject of ongoing investigation.
When tested against the CB 1 agonist, WIN55212, an interesting effect was observed in the presence of modulator. Specifically, the maximal agonist effect (E max ) of WIN55212 to inhibit the electrically-evoked contractions of the mouse vas deferens was significantly reduced by each of Org 27569, Org 27759 and Org 29647, indicative of an insurmountable mode of antagonism (Table 3) ; with the exception of 1µM
Org27569 and Org 27759, the compounds did not significantly alter the pEC 50 values for WIN55212 (Table 3) .
To investigate whether the effects of the compounds were unique to cannabinoid receptors, we conducted experiments with the α 2 adrenoceptor agonist, clonidine. In the presence of DMSO, clonidine inhibited electrically-evoked contractions of the mouse vas deferens with a pEC 50 of 9.00 ± 0.14 and E max of 83 % (95% confidence limits 77.9 -88.1). These values were not significantly different in the presence of 1µM of Org 27569, the pEC 50 and E max being 8.66 ± 0.11 and 77 % (95% confidence limits 70.6 -82.7) respectively.
In order to gain further insight into the apparent dichotomy between modulators effects on agonist affinity, on the one hand, and efficacy, on the other, the data were globally fitted to an operational model of allosterism (see Appendix). This analysis was based on the following assumptions. First, WIN 55,212 was assumed to
This article has not been copyedited and formatted. The final version may differ from this version. The results of this analysis are shown in Figure 6 and Table 4 , and allow us to reconcile our observations with a mechanism whereby the binding cooperativity [
S]GTP S Binding Assay
The insurmountable antagonism mediated by the modulators in the intact mouse vas deferens functional assay is also evident when receptor activity is monitored using a more proximal measure of receptor-effector coupling. In the presence of vehicle, CP55940 produced a stimulation of [ 35 S]GTPγS binding that was 78.65 % (95% confidence limits 66.7 -90.6) above basal binding with a pEC 50 value of 7.93 ± 0.14 ( Figure 7A ). In the presence of 100nM Org 29647, the curve was shifted to the right, although there was no statistically significant effect on E max or pEC 50 , these values being 73.70% (95% confidence limits 36.8 -110) and 7.54 ± This article has not been copyedited and formatted. The final version may differ from this version. Figure 7B ). In the presence of 100nM Org 27569, the curve was shifted to the right, although there was no statistically significant effect on E max of 59.8 % (95% confidence limits 49.9 -69.6). However, when the concentration of Org 27569 was increased to 1µM, the ability of anandamide to stimulate [ 35 S]GTPγS turnover was significantly attenuated, the E max being 17.0 % (95% confidence limits 10.2 -23.7).
Human CB 1 Receptor Reporter Gene Assay
To confirm that the effect of the modulators was not species-specific, additional functional assays were performed using cloned human CB 1 receptors. In the luciferase reporter assay, the Org compounds all behaved as insurmountable antagonists of CP55940 (Figure 8 ), causing a concentration-dependent reduction in the agonist E max value (see Table 5 ).
This article has not been copyedited and formatted. The final version may differ from this version. and elicit a conformational change that increases agonist affinity for the orthosteric binding site.
Despite the positive allosteric enhancement of agonist binding observed in the radioligand binding assays, perhaps the most striking observation from our study was the dissimilitude between the effect on binding affinity and the effect of the same modulators on agonist function (i.e. efficacy). In contrast to the binding assays, the Org compounds did not behave as allosteric enhancers but, rather, as insurmountable antagonists of receptor function;
in the reporter gene assay, the [ 35 S]GTPγS binding assay and the mouse vas deferens assay they elicited a significant reduction in the E max value for CB 1 receptor agonists. The effects of the modulators on function were specifically manifested at the receptor when it was dually occupied by both orthosteric and allosteric ligand, since there was no evidence of agonist or inverse agonist properties of the modulators when tested alone ( Figure 5 ).
There are a number of examples in the recent literature of allosteric modulators that have profound inhibitory effects on orthosteric ligand efficacy while having minimal effects on orthosteric ligand binding (Litschig et al., 1999; Zahnet al., 2002; Watson et al., 2005) , but our study is the first to reveal a striking difference between the magnitude and direction of allosteric modulation of orthosteric affinity, on the one hand, and efficacy, on the other.
Numerous models have been proposed to specifically account for such behaviour at the molecular level (e.g. Hall, 2000; Christopoulos and Kenakin, 2002; Parmentier et al., 2002) .
A key feature of these models is that they contain multiple receptor states that are differentially stabilized by both orthosteric and allosteric ligands. As a consequence, the type of probe and the nature of the assay used can bias the detection of one set of receptor states over another and hence lead to a situation such as that described in our study where different observations are made depending on the experimental endpoint.
This article has not been copyedited and formatted. The final version may differ from this version. These findings have highly significant implications for drug discovery based on allosteric modulators, since they highlight the possibility of misclassification of novel ligands if they are not tested in as full a spectrum of biological assays as possible. In this regard, the operational model of allosterism, as presented in our study, can prove particularly useful.
Like the molecular models described in the preceding paragraph, the operational model we have used is able to accommodate effects of allosteric modulators on both binding and function. However, the operational model has the additional advantage of containing fewer parameters than the molecular models; to our knowledge, this is the first application of such a model to derive quantitative functional parameter estimates for allosteric modulators (Table   4 ). The operational model parameters K A , K B and α have the same mechanistic meaning as they would in any molecular model of allosterism, and their determination can lead to useful information for structure-activity studies. Although the parameter, β, is used only as an empirical proportionality constant, its value can also provide useful insights. For example, β values significantly different to either 1 or 0 would be indicative of a ternary complex (ARB) species that retains the ability to signal in the presence of modulator, but in a modified way.
One point of divergence between the functional and the binding data is with respect to the apparent affinity of the modulators for the mouse CB 1 receptor; in the vas deferens bioassay, the estimated affinity of the Org compounds was higher than that estimated in the binding assay (Table 1 versus Table 4 ). At the moment, the basis for this discrepancy between functional and binding affinity estimates remains unknown. However, a previous study by Pedder et al. (1991) revealed a striking divergence in the affinity estimates of the allosteric modulator, gallamine, at M 2 muscarinic receptors depending on the assay conditions used to determine this value. Indeed, differences in the affinity of the modulator spanned almost two orders of magnitude. It is also worth noting that these same variations in assay conditions had minimal effects on orthosteric ligand affinity estimates (Pedder et al.,
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Taken together, our findings highlight the prospect of manipulating structure-activity to produce compounds that are either allosteric enhancers or allosteric antagonists of the CB 1 receptor. Endocannabinoid levels are significantly increased in models of both inflammatory and neuropathic pain and CB 1 receptor agonists are highly effective analgesics in these models (see Rice et al, 2001; Iversen and Chapman, 2002; Pertwee 2001) . Furthermore, inhibitors of FAAH, the enzyme responsible for the rapid intracellular hydrolysis of anandamide, are antinociceptive in models of both inflammatory and neuropathic pain. These compounds do not display the CNS side-effects that are characteristic of direct CB 1 receptor agonism (Cravatt and Lichtman, 2004) . Allosteric modulators of the cannabinoid CB 1 receptor would also offer the prospect of producing clinically useful compounds that do not display CNS side-effects.
In conclusion, this investigation has provided the first evidence for an allosteric binding site on the cannabinoid CB 1 receptor. This site can be recognized by synthetic small molecules and offers the prospect of a new avenue of CB 1 receptor research that will complement the existing portfolio of selective direct agonists and competitive antagonists. This article has not been copyedited and formatted. The final version may differ from this version. Each symbol represents the mean percent specific binding ± the s.e.mean (n = 4 -8). This article has not been copyedited and formatted. The final version may differ from this version. 
In addition to effects on ligand binding affinity, allosteric modulators may also affect the efficacy of orthosteric agonists. In order to derive a functional model of allosterism that accounts for this possibility, it is first necessary to describe mathematically the effect of an allosteric modulator on the stimulus imparted by an orthosteric agonist to the cell, and the effect of stimulus-response coupling on the final observed response. In accordance with the conventions of classic receptor theory (Furchgott, 1966; Ehlert 1988) , the stimulus (S) is equal to the product of the concentration of orthosteric agonistoccupied receptors and the agonist intrinsic efficacy. In the presence of an allosteric modulator, the stimulus may thus be expressed as:
This article has not been copyedited and formatted. The final version may differ from this version. been shown to closely model the shape of agonist concentration-response curves in many systems (Kenakin and Beek, 1982; Black and Leff, 1983) . Thus, the tissue response (E), expressed as a fraction of the maximal response (E m ), may be described as a function of the stimulus as follows:
This article has not been copyedited and formatted. The final version may differ from this version. 
